CalciMedica Details Pipeline Strategy: Auxora PAH Study Data, CM5480 IND Clearance Expected Mid-2027
CALC has more than doubled off its 52-week low of $0.461 on light trading volume (0.3× avg).
Summary
CalciMedica announced its strategy for utilizing recent proceeds, focusing on advancing its pulmonary hypertension programs. The company plans to initiate a Phase 1b proof-of-concept study for Auxora in pulmonary arterial hypertension (PAH), with data anticipated by mid-2027. Additionally, its oral CRAC channel inhibitor, CM5480, is targeted for IND clearance by mid-2027. This news provides a clear roadmap for key pipeline milestones, following the loan extension and equity conversion announced earlier today.
At the time of this announcement, CALC was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.7M. The 52-week trading range was $0.46 to $7.20. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.